The US Food and Drug Administration has approved Johnson & Johnson’s drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients. The drug release system, ...

Chemotherapy used to target and kill bladder cancer cells may trigger an inflammatory response that ultimately may make the cancer more resistant to treatment, according to new research from ...

Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center and Roswell Park Comprehensive Cancer Center have ...

Rapid developments in muscle-invasive bladder cancer treatment are leading to new approaches to bladder preservation.

Neoadjuvant cisplatin-based chemotherapy plus chemoradiotherapy offers a safe, effective bladder-sparing approach with promising long-term outcomes in nonmetastatic MIBC. Median disease-free survival ...

Chemotherapy used to target and kill bladder cancer cells may trigger an inflammatory response that ultimately may make the cancer more resistant to treatment, according to new research from ...

About one quarter of patients with muscle-invasive bladder cancer (MIBC) may be treated and derive a benefit with the current standard chemotherapy. To better understand why some tumors resist ...

Merck MRK announced that the European Commission has approved its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), and ...

Pfizer expands its oncology portfolio after EU approval for the Keytruda and Padcev regimen, strengthening its cancer ...

Urinary tract infections (UTIs) commonly occur in people who undergo chemotherapy. The treatment can weaken the immune system and damage barriers, such as the skin and mucous membranes, that help ...